Compare Fox Corp Class A (FOXA) vs TG Therapeutics Inc (TGTX) Price & Performance

Fox Corporation (FOXA) trades at $56.69, up 3.32% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results, beating EPS estimates, and completed a transformative $22 billion acquisition of Roku in June 2026. Fundamentals show revenue growth to $16.3B in 2025 with a 13.88% net margin, while valuation metrics appear reasonable with a P/E of 14.73 and EV/EBITDA of 8.42.

The outlook balances strategic positioning through the Roku acquisition against integration risks and leverage concerns. Analyst consensus is evenly split between Buy and Hold with a $67.80 price target suggesting 19.6% upside, but technical indicators remain bearish and projected 2026 cash flow turns negative. Key risks include streaming competition, advertising cyclicality, and debt servicing from the Roku deal.

TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.

The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.